Dongfeng Qu to Biomarkers, Tumor
This is a "connection" page, showing publications Dongfeng Qu has written about Biomarkers, Tumor.
Connection Strength
0.644
-
Epigenetic variants and biomarkers for colon cancer. Am J Pathol. 2012 Jun; 180(6):2205-7.
Score: 0.306
-
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget. 2015 Nov 10; 6(35):37200-15.
Score: 0.098
-
DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2015 Feb; 60(2):509-13.
Score: 0.091
-
Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol. 2012 Apr; 27(4):773-80.
Score: 0.076
-
From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases. Int J Mol Sci. 2024 Jun 12; 25(12).
Score: 0.044
-
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
Score: 0.029